The officers of the company each received restricted stocks (vested bonuses) for meeting the goal of getting at least 4 countries approved in Europe. They did not buy them. There are normally conditions on selling them.
The more important activity was the $40 million worth of A preferred stocks that investors bought showing that there is a belief in this company. It places a strong bottom at $2.91 in my opinion. Also the wording of the transaction ties conversion to approval by the FDA; so there is still life in a USA approval.
Although I was hoping for a big pharma buyout, this is a good thing but may take more time than I'm willing to wait with my 33,000 shares. I'll watch it for awhile longer. Still waiting for the FDA minutes. If you have the time and fortitude you could accumulate on dips below $2.91.